BRPI0517387A - oligonucleotìdeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas - Google Patents

oligonucleotìdeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas

Info

Publication number
BRPI0517387A
BRPI0517387A BRPI0517387-6A BRPI0517387A BRPI0517387A BR PI0517387 A BRPI0517387 A BR PI0517387A BR PI0517387 A BRPI0517387 A BR PI0517387A BR PI0517387 A BRPI0517387 A BR PI0517387A
Authority
BR
Brazil
Prior art keywords
allergy
treatment
antisense oligonucleotides
proliferation
neoplastic cells
Prior art date
Application number
BRPI0517387-6A
Other languages
English (en)
Inventor
Khalid Zemzoumi
Paolo Renzi
Original Assignee
Topigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topigen Pharmaceuticals Inc filed Critical Topigen Pharmaceuticals Inc
Publication of BRPI0517387A publication Critical patent/BRPI0517387A/pt
Publication of BRPI0517387A8 publication Critical patent/BRPI0517387A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

OLIGONUCLEOTìDEOS ANTI-SENSO PARA O TRATAMENTO DE ALERGIA E PROLIFERAçãO DE CéLULAS NEOPLASICAS. São fornecidos oligonucleotídeos anti-sentido para o tratamento e/ou a prevenção de pelo menos um de asma, alergia, hipereosinofilia, inflamação geral e câncer. Os oligonucleotídeos são direcionados contra seqüências de ácidos nucléicos que codificam um receptor selecionado do grupo que consiste em um receptor de CCR3 e uma subunidade comum dos receptores de IL-3, IL-5 e GM-CSF.
BRPI0517387A 2004-10-29 2005-10-27 Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas BRPI0517387A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62320604P 2004-10-29 2004-10-29
PCT/CA2005/001656 WO2006045202A1 (en) 2004-10-29 2005-10-27 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation

Publications (2)

Publication Number Publication Date
BRPI0517387A true BRPI0517387A (pt) 2008-10-07
BRPI0517387A8 BRPI0517387A8 (pt) 2017-07-11

Family

ID=36226992

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517387A BRPI0517387A8 (pt) 2004-10-29 2005-10-27 Oligonucleotídeos anti-senso para o tratamento de alergia e proliferação de células neoplásicas

Country Status (12)

Country Link
US (2) US8119790B2 (pt)
EP (1) EP1812075B1 (pt)
JP (1) JP5314283B2 (pt)
CN (1) CN101087623B (pt)
AU (1) AU2005299218B2 (pt)
BR (1) BRPI0517387A8 (pt)
CA (1) CA2584457C (pt)
ES (1) ES2450929T3 (pt)
MX (1) MX2007005083A (pt)
NZ (1) NZ554723A (pt)
RU (1) RU2416412C2 (pt)
WO (1) WO2006045202A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285961A4 (en) 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
PL2563920T3 (pl) 2010-04-29 2017-08-31 Ionis Pharmaceuticals, Inc. Modulacja ekspresji transtyretyny
JP2014511181A (ja) * 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) * 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) * 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5646265A (en) * 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US5874211A (en) 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
FR2734147B1 (fr) 1995-05-19 1997-10-10 Klein Jean Michel Dispositif d'osteosynthese implantable
US6825174B2 (en) * 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US6229006B1 (en) 1995-12-22 2001-05-08 Smithkline Beecham Corporation Use of antisense oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
EP1012190A4 (en) 1996-04-26 2004-04-28 Merck & Co Inc Eotaxin receptor from eosinophils
WO1997041225A2 (en) 1996-04-26 1997-11-06 Incyte Pharmaceuticals, Inc. Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr]
US5807708A (en) * 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
CA2304312A1 (en) 1997-09-17 1999-03-25 East Carolina University Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
DE69934227T2 (de) 1998-06-19 2007-10-04 Mcgill University, Montreal Auf Beta-Arabinose und dessen Analoga basierte Antisense-Oligonukleotide
HK1042706A1 (zh) 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
US6175004B1 (en) 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
BR0006019A (pt) 1999-04-06 2001-03-13 Univ East Carolina Oligonucleotìdeo de anti-sentido de adenosina baixo, composições, kit & método para tratamento de distúrbios de vias aéreas associados com broncoconstricção, inflamação pulmonar, alergia(s) & depleção de surfactante
EP1315807B1 (en) 2000-09-06 2005-04-20 McGILL UNIVERSITY Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2003004511A2 (en) * 2001-07-06 2003-01-16 Topigen Pharmaceutique Inc.. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
CA2465129A1 (en) 2001-10-29 2003-05-08 Mcgill University Acyclic linker-containing oligonucleotides and uses thereof
US8278103B2 (en) 2002-02-01 2012-10-02 Mcgill University Oligonucleotides comprising alternating segments and uses thereof

Also Published As

Publication number Publication date
RU2416412C2 (ru) 2011-04-20
CA2584457A1 (en) 2006-05-04
AU2005299218A1 (en) 2006-05-04
JP5314283B2 (ja) 2013-10-16
JP2008517953A (ja) 2008-05-29
BRPI0517387A8 (pt) 2017-07-11
CA2584457C (en) 2012-10-23
US8202851B2 (en) 2012-06-19
MX2007005083A (es) 2007-10-03
EP1812075A1 (en) 2007-08-01
US8119790B2 (en) 2012-02-21
EP1812075B1 (en) 2013-12-11
AU2005299218B2 (en) 2012-04-12
EP1812075A4 (en) 2010-04-07
ES2450929T3 (es) 2014-03-25
RU2007119777A (ru) 2008-12-10
CN101087623A (zh) 2007-12-12
US20120065249A1 (en) 2012-03-15
US20090215861A1 (en) 2009-08-27
CN101087623B (zh) 2012-09-26
AU2005299218A2 (en) 2008-10-30
NZ554723A (en) 2009-12-24
WO2006045202A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
Vishnubalaji et al. Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer
WO2011123621A3 (en) 2' and 5' modified monomers and oligonucleotides
EP2194129A3 (en) Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
EP2666859A3 (en) Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
EP2527444A3 (en) Antisense oligonucleotide modulation of stat3 expression
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2009120878A3 (en) Non-natural ribonucleotides, and methods of use thereof
WO2006047842A3 (en) Modified nucleosides for rna interference
NO20084712L (no) Nye farmasoytiske forbindelser
EP4253544A3 (en) Modified messenger rna comprising functional rna elements
WO2011005860A3 (en) 5' phosphate mimics
EP1750771A4 (en) PANCREAS MICRO RNA AND METHOD OF SUPPRESSING IT
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
WO2010080129A3 (en) Extended dicer substrate agents and methods for the specific inhibition of gene expression
MX2011013176A (es) Motivos de modificación química para inhibidores y miméticos del miarn.
BRPI0517613A (pt) oligonucleotìdeos lna e tratamento de cáncer
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
Maalouf et al. Changes in microRNA expression during maturation of the bovine corpus luteum: regulation of luteal cell proliferation and function by microRNA-34a
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
WO2008113111A8 (en) Assay for gene expression
PE20140647A1 (es) Metodo para tratamiento de cancer de pulmon de celulas no pequenas
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
WO2016164463A1 (en) Methods for reactivating genes on the inactive x chromosome

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25A Requested transfer of rights approved

Owner name: PHARMAXIS LTD (AU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]